Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Google Secures Pentagon AI Deal for Classified Projects 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
SAN DIEGO, May 05, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, will announce its financial results for the first quarter ending March 31, 2017, before the market opens on Wednesday, May 10, 2017.
The company will hold a conference call and simultaneous webcast at 8:30 AM Eastern Time (5:30 AM Pacific Time) on Wednesday, May 10, 2017 to discuss the company's financial results and provide a business update. Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 10811814. Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event. The conference call will also be webcast live at: http://edge.media-server.com/m/p/8wft6fu5.
A replay of the call will be available through May 17, 11:30 am ET by calling (855) 859-2056 (U.S.) or (404) 537-3406 (international), using passcode 10811814. An archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics website located at http://investor.obalon.com in the “News & Events” section.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 [email protected] Media: Megan Driscoll EvolveMKD Office Phone: +1 646 517 4220 [email protected]
